Xenon Pharmaceuticals Inc XENE Stock Analysis: Price, Forecast, and News

© 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer.

With a https://1investing.in//sales ratio of 241.09, XENON PHARMACEUTICALS INC has a higher such ratio than 98.6% of stocks in our set. Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive. Provide specific products and services to you, such as portfolio management or data aggregation.

Comcast Increases Dividend by $0.08 to $1.16 Per Share on an Annualized Basis In 2023

The volatility ratio for the week is 3.69%, and the volatility levels for the past 30 days are at 4.30% for Xenon Pharmaceuticals Inc. The simple moving average for the last 20 days is 1.12% for XENE stock, with a simple moving average of -3.02% for the last 200 days. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan…

This site is protected by re2 stocks that could make you richTCHA and the Google Privacy Policy and Terms of Service apply. Only 2 people have added Xenon Pharmaceuticals to their MarketBeat watchlist in the last 30 days. 3 people have searched for XENE on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Xenon Pharmaceuticals Announces Pricing of $250.0 Million Public Offering

Results are interpreted as buy, sell or hold signals, each with numeric ratings and summarized with an overall percentage buy or sell rating. After each calculation the program assigns a Buy, Sell, or Hold value with the study, depending on where the price lies in reference to the common interpretation of the study. For example, a price above its moving average is generally considered an upward trend or a buy. The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock.

JSI uses funds from your Treasury Account to purchase T-bills in increments of $100 “par value” (the T-bill’s value at maturity). The value of T-bills fluctuate and investors may receive more or less than their original investments if sold prior to maturity. T-bills are subject to price change and availability – yield is subject to change. Investments in T-bills involve a variety of risks, including credit risk, interest rate risk, and liquidity risk. As a general rule, the price of a T-bills moves inversely to changes in interest rates. See Jiko U.S. Treasuries Risk Disclosures for further details.

Stock Traders Purchase High Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)

It’s calculated by averaging the closing stock price over the previous 50 trading days. The chart below shows how a company’s share price and consensus price target have changed over time. The lighter blue line represents the stock’s consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock. Enterprise Value is a measure of a company’s total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company’s balance sheet.

The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. Over the past 33 months, XENE’s revenue has gone up $6,342,000.The table below shows XENE’s growth in key financial areas . Revenue growth over the past 12 months for XENON PHARMACEUTICALS INC comes in at -48.83%, a number that bests merely 4.31% of the US stocks we’re tracking.

The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders. Most biotech companies such as Xenon Pharmaceuticals burn cash, and until they make a true shift to commercialization, they trade at lofty valuations. Let’s dive into what Xenon announced and why this is big news for investors in XENE stock. NewsHeater is specialized on the investments in tech sphere. Its specialists are interested in stocks that have been undervalued by different reasons.

What analysts recommend for XENE stock, on a scale from 1 to 5. Access unmatched financial data, news and content in a highly-customised workflow experience on desktop, web and mobile. Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services. While estimates vary, Xenon’s experimental epilepsy drug is expected to compete in a market worth close to $7 billion at present. What’s more, this particular drug market is on track to grow at a compound annual growth rate of approximately 6.6%, according to Coherent Market Insights.

A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations.

Pre-Open Stock Movers 06/23: Snowflake Gains on Upgrade, Accenture Falls Post Earnings (more…)

A stock’s beta measures how closely tied its price movements have been to the performance of the overall market. Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

Fusion Mediawould like to remind you that the data contained in this website is not necessarily real-time nor accurate. XEN1101 Phase 3 epilepsy program continues to advance in focal onset seizures and primary generalized tonic clonic seizures Topline data from XEN1101 Phase 2 X-NOVA clinical trial… Keep in mind that other fees such as regulatory fees, Premium subscription fees, commissions on trades during extended trading hours, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see Open to the Public Investing’s Fee Schedule to learn more.

Alternative Assets purchased on the Public platform are not held in an Open to the Public Investing brokerage account and are self-custodied by the purchaser. The issuers of these securities may be an affiliate of Public, and Public may earn fees when you purchase or sell Alternative Assets. For more information on risks and conflicts of interest, see these disclosures. A number of hedge funds have recently added to or reduced their stakes in XENE. BNP Paribas Arbitrage SA boosted its stake in Xenon Pharmaceuticals by 1,567.5% in the 1st quarter. BNP Paribas Arbitrage SA now owns 1,334 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 1,254 shares during the last quarter.

• This is an increase of 50% compared to the previous 30 days.
• Monitor the latest movements within the Xenon Pharmaceuticals Inc real time stock price chart below.
• These investments are speculative, involve substantial risks , and are not FDIC or SIPC insured.
• Therefore, investors ought to remember to prudently size such positions in a well-diversified portfolio.
• Apex Clearing Corporation, our clearing firm, has additional insurance coverage in excess of the regular SIPC limits.

Advisors Asset Management Inc. acquired a new stake in Xenon Pharmaceuticals in the 1st quarter worth about $66,000. Finally, UBS Group AG boosted its stake in Xenon Pharmaceuticals by 102.1% in the 2nd quarter. UBS Group AG now owns 2,472 shares of the biopharmaceutical company’s stock worth $76,000 after buying an additional 1,249 shares during the last quarter. 92.49% of the stock is owned by institutional investors and hedge funds. The biotech’s shares, in fact, jumped by as much as 98%, on extremely heavy volume, before 8 a.m. XENE’s stock has seen a -1.32% decrease for the week, with a -2.93% drop in the past month and a -7.96% fall in the past quarter.